Epidemiology and resistance patterns of urinary tract infection pathogens: A three-year study in eight hospitals in Lebanon
Figures
Abstract
Background
Urinary tract infections (UTIs) are a prevalent disease worldwide, and increasing antimicrobial resistance (AMR) complicates empirical therapy. In Lebanon, recent multicenter data describing the distribution of urinary pathogens and their antimicrobial resistance patterns remain limited. The present study aimed to characterize uropathogens and their antimicrobial resistance patterns among inpatients and outpatient urinary cultures collected across eight hospitals in Lebanon between 2021 and 2023, and to compare resistance patterns between community-acquired and healthcare-associated UTIs.
Materials and Methods
This study is a retrospective cohort study of positive urine cultures in the laboratory records between January 2021, and December 2023, from eight hospitals in Lebanon.
Results
A total of 16,954 urine culture samples were analyzed. Gram–negative bacteria were responsible for 81% of positive urine cultures, with Escherichia coli (E. coli) (70.3%), Klebsiella pneumoniae (K. pneumoniae) (12.4%), Pseudomonas aeruginosa (P. aeruginosa) (4.8%), Proteus mirabilis (P. mirabilis) (4.3%), and Enterococcus faecalis (E. faecalis) (4%) being the prevalent pathogens. E. coli showed resistance to trimethoprim-sulfamethoxazole (51%), fluoroquinolones (48%), third-generation cephalosporins (45%), and nitrofurantoin (12%). Third-generation cephalosporins and fluoroquinolone resistance in healthcare-associated E. coli strains was significantly higher. K. pneumoniae resistance to antibiotics included nitrofurantoin (61%), trimethoprim-sulfamethoxazole (42%), fluoroquinolones (40%), and third-generation cephalosporins (39%). Among healthcare-associated isolates E. coli (35%) was the most common, followed by Candida albicans (C. albicans) (15%), P. aeruginosa (7.6%), and K. pneumoniae (7.1%). P. aeruginosa resistance to carbapenems (40%) and fluoroquinolones (28%) is higher in healthcare-acquired setting compared to the community setting – found to be 36.08% and 37.3% respectively. This study confirms increasing antimicrobial resistance in Lebanon, consistent with trends reported in other countries.
Citation: Eid S, Karam M, Jamal O, Attieh R, Youssef S, Sfeir Y, et al. (2026) Epidemiology and resistance patterns of urinary tract infection pathogens: A three-year study in eight hospitals in Lebanon. PLoS One 21(11): e0362069. https://doi.org/10.1371/journal.pone.0362069
Editor: Mario Milazzo, UNIPI: Universita degli Studi di Pisa, ITALY
Received: March 17, 2026; Accepted: October 20, 2026; Published: November 20, 2026
Copyright: © 2026 Eid et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: The author(s) received no specific funding for this work.
Competing interests: Authors Mona Youssef, Hanane El Ahmadieh, Emma Abboud, Edmond Abboud, Zeina Shatila, Mohammad Abdallah, and Kamar El Hajj Sleiman are affiliated with Mount Lebanon Hospital, Haykel Hospital, or the Middle East Institute of Health. These institutions had no role in the study design, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Introduction
Urinary tract infections (UTIs) are a major cause of morbidity worldwide. Appropriate management is essential to prevent complications and support guiding antimicrobial stewardship. In the era of antimicrobial resistance (AMR), effective empirical therapy relies on understanding the prevalent uropathogens and their local resistance patterns [1,2]. Identifying the region-specific etiologies and resistance patterns is therefore critical in optimizing empirical treatment [2].
In Lebanon, inappropriate antibiotic use has significantly contributed to rising resistance among uropathogens [3–11]. Multiple studies have documented increasing rates of extended-spectrum beta-lactamase (ESBL) production, particularly among E. coli, with notable regional variation over time [5,9–11]. More recent data demonstrate a continued rise in overall resistance and ESBL production among E. coli and P. mirabilis, alongside an emerging increase in carbapenem resistance among K. pneumoniae and Enterobacter cloacae (E. cloacae) [10].
Given the dynamic nature of antimicrobial resistance, continued surveillance is critical to ensure that empirical antibiotic treatment guidelines remain evidence–based and reflect contemporary local resistance patterns [2]. Despite previous studies, recent nationwide data on urinary pathogen resistance in Lebanon remains limited. This study aims to characterize uropathogens and their antimicrobial resistance patterns among inpatient and outpatient urine cultures collected across multiple hospitals in Lebanon between January 2021, and December 2023, with comparisons between community-acquired and healthcare-associated infections and prior local and international data.
Materials and methods
Study design and setting
This multicenter retrospective study was conducted across eight hospitals in Beirut, Mount Lebanon, and North Lebanon. The study included urine cultures collected between January 01, 2021, and December 31, 2023. The participating institutions were LAU Medical Center–Rizk Hospital, LAU Medical Center–Saint John’s Hospital, Haykel Hospital, Mount Lebanon Hospital University Medical Center, Middle East Institute of Health, Al-Zahraa Hospital University Medical Center, Makassed General Hospital, and Al-Hayat Hospital.
Study population and data collection
All urine cultures yielding bacterial or fungal microorganisms during the study period were included in the analysis. A positive urine culture was defined as a urine specimen from which a bacterial or fungal microorganism was isolated and reported by the participating microbiology laboratory. Clinical information regarding urinary symptoms, culture indication, and clinical diagnosis was not consistently available; therefore, asymptomatic bacteriuria and contaminated specimens could not be reliably distinguished from clinically diagnosed urinary tract infections and were not systematically excluded. Repeat or duplicate cultures were systematically excluded.
Data were retrospectively extracted from the microbiology laboratory records using a standardized case report form. Variables collected included patient age and sex, date of urine culture, culture origin (community-acquired or healthcare-associated), urinalysis findings, Gram stain, isolated pathogen, and antimicrobial susceptibility results (antibiogram). Data extraction was performed between June 3, 2024, and March 2, 2025.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing and interpretation were performed according to the procedures and interpretive criteria used by the microbiology laboratories of the participating hospitals. Six hospitals used Clinical and Laboratory Standards Institute (CLSI) guidelines. Whereas Middle East Institute of Health – University Hospital uses European Committee on Antimicrobial Susceptibility Testing (EUCAST), and Al-Hayat Hospital used either CLSI or European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria according to the laboratory procedure and the antimicrobial-organism combination tested. For the pooled analysis, antimicrobial susceptibility results were analyzed according to the susceptibility interpretation reported by each participating laboratory. Results from Al-Hayat Hospital were included as reported, whether interpreted according to CLSI or EUCAST criteria; no post-hoc reclassification between CLSI and EUCAST breakpoints was performed.
Definitions of infection origin
Community-acquired urinary infections were defined as positive urine culture obtained outside of the hospital setting or within 48 hours of hospital admission. Healthcare-associated urinary infections were defined as culture obtained more than 48 hours after hospital admission or within one month of hospital discharge.
Definitions of antimicrobial resistance
Fluoroquinolone resistance was defined as resistance to ciprofloxacin and/or levofloxacin. Third-generation cephalosporin resistance was defined as resistance to ceftriaxone and/or ceftazidime. Finally, carbapenem resistance was defined as resistance to ertapenem for Enterobacterales (E. coli, K. pneumoniae, Proteus spp., Enterobacter spp., Citrobacter spp., Morganella spp., Serratia spp.), while it was defined as resistance to meropenem and/or imipenem for Pseudomonas spp. and Acinetobacter spp.
Study endpoints
The primary outcome was the prevalence of antimicrobial resistance among urinary isolates during the study period. Secondary outcomes included differences in antimicrobial resistance patterns between community-acquired and healthcare-associated urinary infections. Resistance was evaluated according to the antimicrobial-organism combinations reported by the participating microbiology laboratories.
Ethical approval
The study was approved by the Institutional Review Board (IRB) of the Lebanese American University (LAUIRB approval number: LAUMCRH.RH1.4/Mar/2024.). The study was conducted in compliance with the principles of the Declaration of Helsinki.
Statistical analysis
All statistical analyses were performed using SPSS version 27 and included descriptive statistics and inferential analysis comparing infection origin.
Inferential analysis assessed differences in resistance patterns between community-acquired infections and healthcare-associated infections. Given the categorical nature of the exposure and outcomes, chi-square tests were used for comparisons across major organism-antibiotic pairings. Potential differences in age, sex, hospital, and year of urine culture between community-acquired and healthcare-associated infections were also assessed. No statistically significant differences were identified for these variables. A p-value <0.05 was considered statistically significant.
Results
A total of 16,954 cases were analyzed. The mean patient age was 66 years, and 68.5% were female. Gram–negative organisms accounted for 81.3% of positive cultures, followed by gram–positive organisms (12%) and fungi (6.7%) [Fig 1].
Among 13,788 gram–negative isolates, E. coli was the most frequently identified microbe (70.3%), followed by K. pneumoniae (12.4%), P. aeruginosa (4.8%), P. mirabilis (4.4%) and E. cloacae (1.3%) [Fig 2].
The resistance patterns for Enterobacterales species, Pseudomonas species and Acinetobacter species were evaluated for commonly used UTI antibiotics including ampicillin, trimethoprim-sulfamethoxazole, third-generation cephalosporin, fluoroquinolones, carbapenem, fosfomycin, nalidixic acid.
Among Enterobacterales, resistance prevalence ranged from 12.5%–50.8% for fluoroquinolones, 12.2–61.0% for trimethoprim-sulfamethoxazole, 4.7–45.3% for third-generation cephalosporin, 0–10.5% for carbapenem, and 2.6–87.3% for fosfomycin (Table 1).
Among Acinetobacter species, resistance rates were 1.85% to colistin, 43.4% tigecycline, 67.2% to carbapenem, and 83.3% to fosfomycin. For Pseudomonas species, resistance rates were 15.4% to fosfomycin, 29.6% to ceftazidime, 36.1% to ciprofloxacin, and 37.3% to carbapenem (Table 2).
Comparison of resistance patterns between community-acquired and healthcare-associated infections
Among community-acquired isolates the prevalence of E. coli, K. pneumoniae, E. faecalis, P. mirabilis and P. aeruginosa in urine cultures accounted for 60.1%, 10.8%, 4.8%, 3.8%, and 3.2% respectively. While in the healthcare-associated isolates, the distribution was found to be 35.2%, 9.2%, 4.2%, 4.0%, and 7.6% respectively (Table 3).
Healthcare-associated Proteus species also demonstrated higher resistance rates, with statistical significance limited to carbapenem and fosfomycin. No significant differences in resistance were observed for Pseudomonas species. Enterococcus resistance to ampicillin, teicoplanin, and vancomycin was higher in healthcare-associated infections, with statistical significance observed for ampicillin (Table 3).
Discussion
Gram–negative pathogens
E. coli and K. pneumoniae were the predominant uropathogens, consistent with previous Lebanese studies. The distribution of community-acquired UTIs caused by E. coli, K. pneumoniae, P. aeruginosa, E. faecalis, and P. mirabilis was comparable to the literature, with a lower incidence of healthcare-associated infections reported by E. coli, K. pneumoniae, and P. aeruginosa [3,5,12,13].
Increasing resistance in E. coli UTIs represents a major global concern. Lebanese studies have reported escalating resistance to third-generation cephalosporins and fluoroquinolones, largely driven by ESBL-producing strains, a trend that persists in the current analysis and underscores the need for strengthened antimicrobial stewardship [11,14]. Meta-analyses further demonstrate rising community detection of ESBL-producing strains, indicating that resistance is no longer confined to hospital environments [15]. The high prevalence of ampicillin resistance among E. coli isolates in this study’s cohort (76.8%) suggests that ampicillin should no longer be considered an appropriate empirical treatment option for urinary tract infections in Lebanon. These findings further support the need updated empirical antimicrobial resistance surveillance data.
International data mirrors these findings. Large studies from the United Kingdom and United States report rising resistance to fluoroquinolones, nitrofurantoin, and ESBL-producing Enterobacterales, consistent with the resistance patterns observed in this study [16,17]. Meta-analyses further highlight the global dissemination of resistant E. coli across human, animal and environmental reservoirs [18,19]. However, because the present study was limited to human clinical isolates and did not include animal or environmental sampling, any interpretation of intersectoral transmission must remain cautious. Lebanese data nevertheless show that resistant E. coli is not confined to the human sector. In a nationwide Lebanese poultry study, Dandachi et al. found that 77.5% of sampled farms had at least one multidrug-resistant gram–negative isolate, with E. coli representing 92% of recovered strains; ESBL, AmpC, and ESBL/AmpC co-production were frequently detected, and co-resistance to ciprofloxacin, gentamicin, and trimethoprim-sulfamethoxazole was also reported [20]. A more recent nationwide genomic survey of Lebanese broiler farms further demonstrated widespread carriage of ESC-resistant E. coli, with 52 of 56 farms harboring resistant isolates; among sequenced multidrug-resistant E. coli, ESBL, plasmid-mediated AmpC, and ESBL/AmpC co-producers accounted for 60%, 27.6%, and 12.4%, respectively. Most isolates were also ciprofloxacin-resistant, and 19/102 carried the mobile colistin resistance gene mcr-1. These findings indicate that poultry in Lebanon may represent an important reservoir of multidrug-resistant E. coli carrying clinically relevant resistance determinants. Therefore, the overlap between resistance patterns observed in clinical isolates and those reported in Lebanese poultry supports the need for integrated antimicrobial resistance surveillance across human, veterinary, food-chain, and environmental sectors [21]. Although this study’s data do not establish cross-sector transmission, evidence of resistant E. coli reservoirs in Lebanese animal sectors emphasizes the importance of One Health surveillance [18].
The low carbapenem resistance rate observed in this study (2.3%) aligns with previous Lebanese research, indicating that carbapenems remain effective against E. coli-related infections [5]. Nevertheless, global emergence of carbapenem-resistant Enterobacteriaceae (CRE) warrants continued surveillance [5].
The low resistance rate for Fosfomycin (5.84%) supports its continued usage as important treatment option in the management of UTIs, consistent with prior Lebanese findings [5].
Compared with Lebanese GLASS 2021 data, this study demonstrated higher E. coli resistance to carbapenems and fluoroquinolones, with comparable resistance to third-generation cephalosporins and trimethoprim-sulfamethoxazole. In contrast, K. pneumoniae demonstrated lower resistance to third-generation cephalosporins, carbapenems, and fluoroquinolones, while remaining comparable for trimethoprim-sulfamethoxazole, noting that GLASS data lack detailed institutional information [22].
Comparison with regional and international data provides an important epidemiological context. Resistance rates for E. coli in this study were lower than those reported in Egypt for multiple antibiotic classes, including carbapenems, fluoroquinolones, third-generation cephalosporins, nitrofurantoin and ampicillin [23]. In contrast, post-COVID-19 data from Saudi Arabia demonstrated lower resistance to fluoroquinolones, nitrofurantoin, third-generation cephalosporins, and trimethoprim-sulfamethoxazole, with comparable carbapenem resistance [24]. Compared with data from India, resistance to several first-line agents was higher in this study [25], whereas U.S. data demonstrated higher carbapenem resistance but lower resistance to other agents [26].
For K. pneumoniae, Egyptian data demonstrated higher resistance to third-generation cephalosporins and carbapenems, with lower resistance to nitrofurantoin, and comparable resistance to ampicillin [23]. Regionally, a study in Turkey data showed comparable fluoroquinolone resistance, lower ampicillin resistance, and higher carbapenems and third-generation cephalosporins resistance [27]. In comparison with U.S. data, resistance patterns in this study were comparable for ampicillin, carbapenem and third-generation cephalosporins, but lower for nitrofurantoin and fluoroquinolones [26].
Ampicillin resistance was notably high in Klebsiella (95.8%), Citrobacter (95.8%), to Morganella (95.3%), Serratia (88.5%), and E. coli (76.8%). Earlier Lebanese studies (2009–2012) similarly demonstrated high resistance to ampicillin and amoxicillin/clavulanic acid among common uropathogens (31–79%) [7]. Collectively, these findings suggest that ampicillin is no longer appropriate for empirical treatment of UTIs. These findings support updating local empirical treatment guidelines to reflect this new pattern of resistance in order to improve patient care.
Resistance rates to trimethoprim-sulfamethoxazole is high in Morganella (61.0%), Proteus (55.5%), and E. coli (47.6%), limiting its suitability for empirical therapy in this setting, despite lower resistance observed in Citrobacter species(12.1%). In contrast, resistance rates reported from the United States are lower, suggesting that trimethoprim-sulfamethoxazole may remain an empirical treatment option in selected settings outside Lebanon [28].
Nitrofurantoin resistance was high among Klebsiella, Morganella, and Proteus in this study. Globally, increasing resistance has been reported, with similar trends described in North Lebanon, although organism-specific nitrofurantoin data were not provided [27]. In this study’s cohort, E. coli remained largely susceptible to nitrofurantoin, with a resistance rate of only 12%. Therefore, the declining clinical utility of nitrofurantoin primarily relates to its reduced effectiveness against other common uropathogens, including Klebsiella, Morganella, and Proteus, which demonstrated substantially higher resistance rates in this study [29].
Resistance to third-generation cephalosporin was substantial for Klebsiella (39.4%), Enterobacter (26.8%), and Serratia (23.6%). These findings are consistent with Lebanese reports of increasing extended-spectrum β-lactamase (ESBL)-producing uropathogens, including a South Lebanon study reporting ESBL production in 32.9% of isolates [30]. Similar trends have been reported globally, reinforcing the need for cautious use of third-generation cephalosporins, particularly in severe infections [31].
Fluoroquinolone resistance was high in Klebsiella (40.2%), Proteus (47.3%), and Morganella (43.4%), and moderate in Enterobacter (28.9%) and Serratia (32.7%). These findings are consistent with previous Lebanese and international reports and support a cautious use of fluoroquinolones for empirical therapy [7,13,31,32].
In this study, E. coli and Klebsiella demonstrated low resistance to fosfomycin (5.84% and 23.3%, respectively), supporting its role in the treatment of community-onset cystitis, particularly those caused by E. coli. However, resistance varied markedly among Enterobacterales and was higher in the presence of broader β-lactam resistance. A nine-year Turkish study similarly reported low resistance in E. coli (1.98%) but higher rates in K. pneumoniae (21.6%) and Enterobacter spp. (35.7%); particularly among ESBL-producing strains [33]. These findings underscore the importance of avoiding assumptions of uniform fosfomycin activity across Enterobacterales.
Carbapenem resistance was low among most uropathogens in this study, supporting their continued effectiveness in the treatment of severe infections. Resistance rates were 10.5% in Serratia, 6.4% in Klebsiella, 5.0% in Enterobacter, 2.5% in Citrobacter, and 0.63% in Proteus, while no resistance was observed in Morganella. Despite these favorable findings, carbapenem-resistant UTIs are an emerging concern. In Europe, carbapenem resistance among Enterobacterales in Europe – particularly K. pneumoniae – continues to increase, with blood stream infection rates rising from 10.4% in 2019 to 13.3% in 2023 across EU/EEA [34]. Reported outbreaks in Southern Europe further highlight the need for ongoing surveillance and containment strategies [35].
P. aeruginosa remains a challenging uropathogen due to its intrinsic resistance mechanisms, rapid acquisition of resistance, and biofilm formation, and is recognized globally as a key ESKAPE pathogen [36,37]. Lebanese data highlights the severity of this issue. A multicenter study conducted across four tertiary hospitals in Beirut reported that approximately 15% of isolates were difficult-to-treat resistant (DTR), with nearly one-third exhibiting carbapenem resistance [36]. VIM-2 carbapenemase production predominates among Lebanese isolates, and the detection of carbapenemase-producing strains in livestock suggests broader ecological dissemination [38].
In this study, P. aeruginosa demonstrated low resistance to fosfomycin (15.4%), supporting its potential role in selected UTI cases (Table 2). Resistance to ciprofloxacin, carbapenem, and ceftazidime is comparable to rates reported in previous local studies, suggesting relative stability in resistance patterns over time [39]. Nevertheless, the observed resistance to fluoroquinolones and carbapenems, together with emerging fosfomycin resistance, warrants close monitoring. Although P. aeruginosa UTIs remain infrequent, global and regional data indicate a steady rise in multidrug resistant and extensively drug-resistant isolates, underscoring the importance of continued surveillance [37,40].
This study identified 76 Acinetobacter species urinary isolates. Resistance was lowest to colistin (1.85%), whereas higher resistance rates were observed to tigecycline (43.4%), carbapenem (67.2%), and fosfomycin (83.3%). These findings highlight the limited therapeutic options available for Acinetobacter-associated UTIs, with colistin an alternative for treatment.
Gram–positive pathogens
Enterococcus remains the most common gram–positive uropathogen worldwide, with E. faecalis predominating over E. faecium. In the present study, Enterococcus spp. accounted for approximately 8% of UTIs, and E. faecalis represented 58% of isolates. Earlier Lebanese data reported low ampicillin resistance in E. faecalis, and moderate resistance rates in E. faecium strains [40]. However, more recent studies demonstrate a steady increase in resistance [14,41,42]. Consistent with this trend, this study’s findings demonstrate ampicillin resistance at 32% and a vancomycin resistance ~12%, indicating a progressive rise in resistance and the emergence of vancomycin-resistant enterococci (VRE), particularly in inpatient settings.
International data demonstrate substantial regional variability in Enterococcus epidemiology and resistance. In Spain, E. faecalis accounted for 19% of UTIs and E. faecium for 4%, with low vancomycin resistance but increasing fluoroquinolone resistance [43]. In a Hungaria study, enterococci accounted for up to 88.5% of Gram-positive urinary isolates, with 31–47% exhibiting high-level aminoglycoside resistance and 0.16% VRE [44]. In contrast, a study from Saudi Arabia documented a higher vancomycin resistance (7%), highlighting the impact of regional resistance pressures [45]. Overall, these findings underscore substantial geographic variation in Enterococcus resistance patterns and vancomycin effectiveness.
Other Gram–positive pathogens also contribute to UTIs. Staphylococcus saprophyticus is a frequent cause of uncomplicated UTIs, accounting for approximately 30% globally and exceeding 40% in young women in some Scandinavian studies [46]. S. aureus is less frequently isolated but remains clinically significant, as its detection in urine may reflect bacteremia or endocarditis rather than primary UTI [44]. In Saudi Arabia, S. aureus, including methicillin-resistant S. aureus (MRSA), accounted for 15% of Gram–positive UTI isolates [47].
Gram–positive bacteria account for a substantial proportion of UTIs (~20% globally, 8% in this study), predominantly due to E. faecalis, which shows increasing resistance to ampicillin and occasional resistance to vancomycin. Although less common, staphylococcal UTIs, including MRSA, remain clinically relevant. These findings stress the need to include Gram–positive pathogens in surveillance and tailoring empirical treatment to local resistance trends.
Fungus
Among the analyzed samples, 1131 urinary isolates were fungal, including 1130 Candida species and one Zygosaccharomyces species. Candida albicans accounted for 73% of isolates, while non-albicans species comprised 27%, consistent with previous reports. Overall, Candida species’ resistance patterns were tested against six antifungals Micafungin, Voriconazole, Flucytosine, Amphotericin B, Caspofungin and Fluconazole; and resistance patterns were found to be 2.2%, 2.8%, 3.9%, 4.9%, 13.5%, and 35% respectively. While C. albicans-specific resistance patterns were found to be 0%, 1.9%, 2.9%, 5.4%, 1%, 16.7%, respectively. These findings suggest generally favorable susceptibility patterns, although increasing fluconazole resistance warrants caution, consistent with prior Lebanese reports [48].
Globally, candiduria accounts for approximately 15% of healthcare-associated UTIs, with C. albicans as the predominant species, followed by C. glabrata and Candida tropicalis [49]. Studies from Turkey and other regions confirm the predominance of C. albicans while documenting a rising proportion of non-albicans species, which are often more resistant to azole antifungals [50]. Similar trends have been reported in Iran and Ethiopia, particularly among hospitalized and pediatric populations [51,52]. Current Infectious Diseases Society of America (IDSA) guidelines recommend against treating asymptomatic candiduria except in high-risk groups, including neutropenic patients, neonates, and individuals undergoing urologic procedures [53]. Fluconazole resistance was notably high in this study (35%), consistent with international reports [49,51]. Amphotericin B and echinocandins largely retained effectiveness, although emerging resistance has been reported [48,50].
Taken together, these findings suggest that while Candida albicans UTIs generally remain responsive to first-line antifungals, the increasing prevalence of non-albicans species and rising azole resistance warrant caution. Species-level identification and susceptibility testing are essential for optimal management.
Nosocomial resistance patterns
In the present study, healthcare-associated (HA) E. coli UTIs demonstrated significantly higher resistance rates than community-acquired infections (68.6% vs 42.1%) (Table 3). This finding aligns with previous Lebanese multicenter data from 2005–2012, which reported hospital resistance of approximately 55%, as well as international data from the United Kingdom documenting rates of 50–60% in hospital settings [11,16]. The observed odds ratio (OR: 3.02) indicates a strong association between hospital exposure and antimicrobial resistance, in line with a 2022 meta-analysis linking healthcare settings to increased prevalence of ESBL-producing E. coli [15]. Additionally, HA ertapenem resistance was markedly higher than community resistance (8.6% vs 1.9%), reflecting the emergence of carbapenem-resistant Enterobacterales (CRE) in Lebanese hospitals – a trend recognized by the World Health Organization as a critical global threat [29,54,55].
Similarly, HA Klebsiella UTIs exhibited higher resistance to third-generation cephalosporins compared with community isolates (61% vs 33.4%). This pattern parallels findings from a South Lebanon multicenter study (2020) and a recent international multicenter study (2024), both of which attributed increased hospital resistance to ESBL production [5,33]. Fluoroquinolone resistance was also more prevalent among HA isolates (45.8% vs. 31.2%). Although rising fluoroquinolone resistance has been reported in outpatient settings in the United States, the higher rates observed in this study’s hospital cohort may reflect increased local antibiotic selective pressure [17].
Among Enterococcus isolates, HA resistance to Ampicillin was approximately double observed in community infections (46.2% vs 23.6%), consistent with previous Lebanese data. Vancomycin resistance was also higher in HA isolates (9.1% vs 1.8%), although these rates remain lower than those reported in U.S. studies, highlighting regional variability in VRE dissemination and outbreak dynamics [7,17].
Healthcare-associated P. mirabilis isolates demonstrated higher resistance to ertapenem compared with community isolates (8% vs 0.8% in community). This contrasts with earlier international reports describing lower carbapenem resistance rates and suggests possible local dissemination of carbapenemase-producing strains, as previously reported in northern Lebanon [31,32].
In contrast, resistance of P. aeruginosa to ceftazidime and meropenem was comparable between HA and community settings. This finding diverges from a nationwide Lebanese study conducted in 2016, which reported higher hospital resistance and may reflect smaller nosocomial sample sizes or the impact of effective local infection control measures [14]. Overall, healthcare-associated UTIs demonstrate higher resistance rates than community-acquired infections, underscoring the need for a tailored inpatient management approach guided by local epidemiological data.
Limitations
The retrospective microbiological nature of the study precluded molecular characterization of resistance mechanisms and assessment of the clinical factors and outcomes associated with resistant uropathogens. Further prospective studies incorporating molecular testing and standardized clinical data are needed to better characterize resistance mechanisms and their clinical correlates in Lebanon.
Conclusion
Gram–negative bacteria, mainly E. coli and K. pneumoniae, were the predominant uropathogens, with increasing resistance to third-generation cephalosporins, fluoroquinolones, and trimethoprim-sulfamethoxazole. Resistance to carbapenems, nitrofurantoin, and fosfomycin remained low, supporting their judicious use. Higher resistance rates in healthcare settings underscore the need for enhanced infection control, ongoing surveillance, and targeted antimicrobial stewardship to optimize therapy and preserve antibiotic efficacy.
Acknowledgments
References
- 1. Abou Heidar NF, Degheili JA, Yacoubian AA, Khauli RB. Management of urinary tract infection in women: A practical approach for everyday practice. Urol Ann. 2019;11(4):339–46. pmid:31649450
- 2. Mortazavi-Tabatabaei SAR, Ghaderkhani J, Nazari A, Sayehmiri K, Sayehmiri F, Pakzad I. Pattern of antibacterial resistance in urinary tract infections: A systematic review and meta-analysis. Int J Prev Med. 2019;10:169. pmid:32133087
- 3. Daoud Z, Afif C. Escherichia coli Isolated from urinary tract infections of lebanese patients between 2000 and 2009: Epidemiology and profiles of resistance. Chemother Res Pract. 2011;2011:218431. pmid:22295204
- 4. Khalife H, Khalife I, Abdel-Sater F, Khalife H. Epidemiology and profiles of antibiotic resistance of bacteria isolated from urinary tract infections in Lebanon. World J Pharm Pharm Sci. 2018;7:120–8.
- 5. Sokhn ES, Salami A, El Roz A, Salloum L, Bahmad HF, Ghssein G. Antimicrobial Susceptibilities and Laboratory Profiles of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates as Agents of Urinary Tract Infection in Lebanon: Paving the Way for Better Diagnostics. Med Sci (Basel). 2020;8(3):32. pmid:32823619
- 6. El-Hajj E, Mrad C, Bou Assi T, Haddad A, Anouty Z, Jurjus A. Prevalence and risk factors of extended spectrum beta lactamase organisms in community-acquired urinary tract infections in Lebanon: a case control study. EuroMediterr Biomed J. 2016;11:148–56.
- 7. Soubra L, Kabbani S, Anwar MF, Dbouk R. Spectrum and patterns of antimicrobial resistance of uropathogens isolated from a sample of hospitalised Lebanese patients with urinary tract infections. J Glob Antimicrob Resist. 2014;2(3):173–8. pmid:27873725
- 8. Moussally M, Zahreddine N, Kazma J, Ahmadieh R, Kan SS, Kanafan ZA. Prevalence of antibiotic-resistant organisms among hospitalized patients at a tertiary care center in Lebanon, 2010-2018. J Infect Public Health. 2021;14(1):12–6.
- 9. Hayajneh WA, Hajj A, Hulliel F, Sarkis DK, Irani-Hakimeh N, Kazan L, et al. Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011-2013. Int J Infect Dis. 2015;35:56–61. pmid:25917963
- 10. Fadlallah M, Salem Sokhn E. Epidemiology and resistance profiles of Enterobacterales in a tertiary care hospital in Lebanon: a 4-year retrospective study. J Infect Dev Ctries. 2023;17(7):986–93. pmid:37515799
- 11. Daoud Z, Salem Sokhn E, Masri K, Matar GM, Doron S. Escherichia coli Isolated from urinary tract infections of Lebanese patients between 2005 and 2012: Epidemiology and profiles of resistance. Front Med (Lausanne). 2015;2:26. pmid:25984513
- 12. Rahme D, Nakkash Chmaisse H, Salameh P. Unraveling the length of hospital stay for patients with urinary tract infections: Contributing factors and microbial susceptibility. Antibiotics (Basel). 2025;14(4):421. pmid:40298568
- 13. Darwich N, Samaha A, Al Nuqaidan H, Tassi A, Fawaz M. Surveillance of multidrug-resistant uropathogenic escherichia coli in hospitalized patients and community settings in the South of Lebanon. BAU Journal - Health and Wellbeing. 2020;3(1).
- 14. Chamoun K, Farah M, Araj G, Daoud Z, Moghnieh R, Salameh P, et al. Surveillance of antimicrobial resistance in Lebanese hospitals: Retrospective nationwide compiled data. Int J Infect Dis. 2016;46:64–70. pmid:26996458
- 15. Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, et al. Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Resist. 2022;4(3):dlac048. pmid:35668909
- 16. Ong A, Mahobia N, Browning D, Schembri M, Somani BK. Trends in antibiotic resistance for over 700,000 Escherichia coli positive urinary tract infections over six years (2014-2019) from a university teaching hospital. Cent European J Urol. 2021;74(2):249–54. pmid:34336246
- 17. Dunne MW, Aronin SI, Yu KC, Watts JA, Gupta V. A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011–2020. BMC Infectious Diseases. 2022;22(1).
- 18. Pormohammad A, Nasiri MJ, Azimi T. Prevalence of antibiotic resistance in Escherichia coli strains simultaneously isolated from humans, animals, food, and the environment: A systematic review and meta-analysis. Infect Drug Resist. 2019;12:1181–97. pmid:31190907
- 19. Lindblom A, Kiszakiewicz C, Kristiansson E, Yazdanshenas S, Kamenska N, Karami N, et al. The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: A prospective comparative study. Sci Rep. 2022;12(1):10048. pmid:35710924
- 20. Dandachi I, Sokhn ES, Dahdouh EA, Azar E, El-Bazzal B, Rolain J-M, et al. Prevalence and characterization of multi-drug-resistant gram-negative bacilli isolated from lebanese poultry: A nationwide study. Front Microbiol. 2018;9:550. pmid:29628921
- 21. Mikhayel M, Leclercq SO, Sarkis DK, Doublet B. Occurrence of the Colistin Resistance Gene mcr-1 and Additional Antibiotic Resistance Genes in ESBL/AmpC-Producing Escherichia coli from Poultry in Lebanon: A Nationwide Survey. Microbiol Spectr. 2021;9(2):e0002521. pmid:34494875
- 22.
World Health Organization. Global antimicrobial resistance surveillance system (GLASS): country profiles. Geneva: World Health Organization. https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-resistance-surveillance-system-glass/glass-country-profiles
- 23. Tarek A, Abdalla S, Dokmak NA, Ahmed AA, El-Mahdy TS, Safwat NA. Bacterial diversity and antibiotic resistance patterns of community-acquired urinary tract infections in mega size clinical samples of egyptian patients: A cross-sectional study. Cureus. 2024;16(1):e51838. pmid:38327928
- 24. AlHemsi HB, Altamimi I, Altamimi A, Alhemsi HB, Alabdulkarim IM, Zawawi A, et al. Shifting trends of antimicrobial resistance patterns among uropathogenic bacteria before and during the COVID-19 pandemic. Cureus. 2024;16(11):e73267. pmid:39650875
- 25. Marepalli NR, Nadipelli AR, Manohar Kumar Jain RJ, Parnam LS, Vashyani A. Patterns of antibiotic resistance in urinary tract infections: A retrospective observational study. Cureus. 2024;16(6):e62771. pmid:39036226
- 26. Ku JH, Bruxvoort KJ, Salas SB, Varley CD, Casey JA, Raphael E, et al. Multidrug resistance of Escherichia coli From outpatient uncomplicated urinary tract infections in a large United States integrated healthcare organization. Open Forum Infect Dis. 2023;10(7):ofad287. pmid:37426945
- 27. Olcay HO, Emektar E, Ertaş İ, Tokgöz ZH, Çevik Y. Evaluation of urine culture results and antibiotic resistance patterns in the emergency department between 2020 and 2023. Glob Emerg Crit Care. 2025.
- 28. Morrill HJ, Morton JB, Caffrey AR, Jiang L, Dosa D, Mermel LA, et al. Antimicrobial resistance of Escherichia coli urinary isolates in the veterans affairs health care system. Antimicrob Agents Chemother. 2017;61(5):e02236-16. pmid:28193660
- 29. Daaboul D, Oueslati S, Rima M, Kassem II, Mallat H, Birer A, et al. The emergence of carbapenemase-producing Enterobacterales in hospitals: a major challenge for a debilitated healthcare system in Lebanon. Front Public Health. 2023;11:1290912. pmid:38074718
- 30. Sobh G, Araj GF, Finianos M, Sourenian T, Hrabak J, Pappagianitsis CC, et al. Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread of blaNDM-5 gene at a Lebanese medical center. Front Cell Infect Microbiol. 2024;14:1407246. pmid:38962322
- 31. Rima M, Oueslati S, Dabos L, Daaboul D, Mallat H, Bou Raad E, et al. Prevalence and molecular mechanisms of carbapenem resistance among gram-negative Bacilli in three hospitals of Northern Lebanon. Antibiotics (Basel). 2022;11(10):1295. pmid:36289953
- 32. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43–50. pmid:20129148
- 33. Tanrıverdi-Çaycı Y, Güne DB, Ertokatlı M, Hacıeminoğlu-Ülker K, Birinci A. Prevalence of Fosfomycin Resistance Among Enterobacterales Isolates in A Tertiary Care Hospital from Turkey. Infect Dis Clin Microbiol. 2022;4(4):252–7. pmid:38633718
- 34. Budia-Silva M, Kostyanev T, Ayala-Montaño S, Bravo-Ferrer Acosta J, Garcia-Castillo M, Cantón R, et al. International and regional spread of carbapenem-resistant Klebsiella pneumoniae in Europe. Nat Commun. 2024;15(1):5092. pmid:38877000
- 35. European Centre for Disease Prevention and Control. Carbapenem-resistant Enterobacterales – third update. Stockholm: ECDC. 2025.
- 36. Itani R, Khojah HMJ, Shuhaiber P, Raychouni H, Dib C, Hassan M, et al. Incidence and risk factors of resistant Pseudomonas aeruginosa infections: A multicenter study in Lebanese tertiary hospitals. BMC Infect Dis. 2025;25(1):1048. pmid:40836228
- 37. Ali A, Abbas H, Zhang Y, Wang Y, Wang T. Strategies to combat multidrug-resistant Pseudomonas aeruginosa: state-of-the-art and future perspectives. Front Microbiol. 2024;15:1374466.
- 38. Dabbousi AA, Dabboussi F, Hamze M, Osman M, Kassem II. The emergence and dissemination of multidrug resistant Pseudomonas aeruginosa in Lebanon: Current status and challenges during the economic crisis. Antibiotics (Basel). 2022;11(5):687. pmid:35625331
- 39. Gad GF, el-Domany RA, Ashour HM. Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt. J Urol. 2008;180(1):176–81. pmid:18499192
- 40. Sendra E, Fernández-Muñoz A, Zamorano L, Oliver A, Horcajada JP, Juan C, et al. Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: A microbiological and clinical perspective. Infection. 2024;52(4):1235–68. pmid:38954392
- 41. Zouain MG, Araj GF. Antimicrobial resistance of Enterococci in Lebanon. Int J Antimicrob Agents. 2001;17(3):209–13. pmid:11282266
- 42. Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis. 2018;18(12):e379–94. pmid:30292478
- 43. Fernández-Espigares L, Hernández-Chico I, Expósito-Ruiz M, Rosales-Castillo A, Navarro-Marí JM, Gutiérrez-Fernández J. Antibiotic resistance changes in gram-positive bacteria from urine cultures: Development analysis in a health area of South-East Spain. Antibiotics (Basel). 2023;12(7):1133. pmid:37508228
- 44. Gajdács M, Ábrók M, Lázár A, Burián K. Increasing relevance of Gram-positive cocci in urinary tract infections: A 10-year analysis of their prevalence and resistance trends. Sci Rep. 2020;10(1):17658. pmid:33077890
- 45. Thabit AK, Alabbasi AY, Alnezary FS, Almasoudi I. An overview of antimicrobial resistance in Saudi Arabia (2013–2023) and the need for national surveillance. Microorganisms. 2023;11(8):2086.
- 46. Urmi UL, Jahan N, Nahar S, Rana M, Sultana F, Hossain B. Gram-positive uropathogens: Empirical treatment and emerging antimicrobial resistance. Biomed Res Clin Pract. 2019;4(1):1–4.
- 47. Alkahtani AM, Alqahtani AJ, Alamri A, Assiry MM, Elfaki M, Shabi YM, et al. Burden of gram-positive bacteria from urinary tract infection: A four-year retrospective study in a tertiary health setting in southern Saudi Arabia. PLoS One. 2025;20(8):e0328042. pmid:40748877
- 48. Hassoun N, Kassem II, Hamze M, El Tom J, Papon N, Osman M. Antifungal use and resistance in a lower-middle-income country: The case of Lebanon. Antibiotics (Basel). 2023;12(9):1413. pmid:37760710
- 49. Gharaghani M, Taghipour S, Halvaeezadeh M, Mahmoudabadi AZ. Candiduria; A review article with specific data from Iran. Turk J Urol. 2018;44(6):445–52. pmid:31587699
- 50. Aksoyalp ZŞ, Temel A. Urinary tract infections and fungal infections associated with SGLT-2 inhibitors and metformin combination: A real-world study from 2013 to 2023 based on the FAERS database. J Clin Pract Res. 2024;46(3):282–9.
- 51. Bitew A, Zena N, Abdeta A. Bacterial and fungal profile, antibiotic susceptibility patterns of bacterial pathogens and associated risk factors of urinary tract infection among symptomatic pediatrics patients attending St. Paul’s Hospital Millennium Medical College: A cross-sectional study. Infect Drug Resist. 2022;15:1613–24. pmid:35418760
- 52. Altinbaş R, Bi̇ldi̇ri̇ci̇ Y. Distribution of yeasts in fungal urinary tract infections from a tertiary care hospital. J Med Palliative Care. 2023;4(4):296–301.
- 53. Dias V. Candida species in the urinary tract: Is it a fungal infection or not?. Future Microbiol. 2020;15(2):81–3.
- 54. Fadlallah M, Salman A, Salem-Sokhn E. Updates on the status of carbapenem-resistant enterobacterales in Lebanon. Int J Microbiol. 2023;2023:8831804. pmid:37283804
- 55.
World Health Organization. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016–2017. Geneva: World Health Organization. 2017.